319 related articles for article (PubMed ID: 24033095)
1. Agomelatine in depression.
Smeraldi E; Delmonte D
Expert Opin Drug Saf; 2013 Nov; 12(6):873-80. PubMed ID: 24033095
[TBL] [Abstract][Full Text] [Related]
2. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
3. Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
Srinivasan V; De Berardis D; Shillcutt SD; Brzezinski A
Expert Opin Investig Drugs; 2012 Oct; 21(10):1503-22. PubMed ID: 22876742
[TBL] [Abstract][Full Text] [Related]
4. The preclinical discovery and development of agomelatine for the treatment of depression.
Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
[TBL] [Abstract][Full Text] [Related]
5. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
[TBL] [Abstract][Full Text] [Related]
7. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
8. A review of the efficacy and tolerability of agomelatine in the treatment of major depression.
Ghosh A; Hellewell JS
Expert Opin Investig Drugs; 2007 Dec; 16(12):1999-2004. PubMed ID: 18042007
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine: a preliminary review of a new antidepressant.
Zupancic M; Guilleminault C
CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
[TBL] [Abstract][Full Text] [Related]
10. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Olié JP; Kasper S
Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
[TBL] [Abstract][Full Text] [Related]
12. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
[TBL] [Abstract][Full Text] [Related]
13. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
14. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine: a narrative review.
Demyttenaere K
Eur Neuropsychopharmacol; 2011 Sep; 21 Suppl 4():S703-9. PubMed ID: 21835598
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of agomelatine in previously-treated depressed patients.
Kasper S; Hajak G
Eur Neuropsychopharmacol; 2013 Aug; 23(8):814-21. PubMed ID: 23820051
[TBL] [Abstract][Full Text] [Related]
18. Hypomania soon after shifting from paroxetine to agomelatine in a middle-aged woman with depression.
Tu KY; Lin PY
Clin Neuropharmacol; 2014; 37(3):82-3. PubMed ID: 24824663
[TBL] [Abstract][Full Text] [Related]
19. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
